BioRestorative Therapies, Inc. (BRTX)
BRTXNASDAQ-CMManaged Health Care
$1.47
-0.0859 (-5.51%) today
Closed, Nov 12, 4:00 PM ET
- Market cap
- $2.04m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.28 to $28.99
- Average volume
- –
- Previous close
- $1.56
Earnings
next estimate $-2.60Next report
Sep 2025
0.0%
Dec 2025
0.0%
Mar 2026
+36.7%
estimate reported, and the surprise
Financials
| Quarter | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | $303.0k | $12.0k | $20.0k | $23.0k |
| Gross profit | $295.0k | $1,000 | $18.0k | $16.0k |
| Operating income | -$3.31m | -$3.71m | -$3.83m | -$3.39m |
| Net income | -$2.66m | -$3.04m | -$3.21m | -$2.15m |
Last four quarters: revenue $358.0k, margin -3088.3%, free cash flow –
News
8 latest- BioRestorative Therapies Consensus Price Target Increased by 1,900% to $163.20Fintel · Sep 15, 2026
- Alvotech (ALVO) Reports Q2 Loss, Beats Revenue EstimatesZacks · Aug 19, 2026
- Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue EstimatesZacks · Aug 14, 2026
- Weekly Buzz: AZN, JNJ Get FDA Nod; LLY To Acquire Curevo; APGE Advances Zumilokibart RTTNews · May 29, 2026
- Kaos Capital Takes 4.9% Stake In BioRestorative Therapies; Stock Surges In Pre-Market RTTNews · May 27, 2026
- BioRestorative Completes Phase 2 Dosing For BRTX-100 For Lumbar Disc Disease; Shares Climb By 20% RTTNews · May 27, 2026
- BioRestorative Completes Phase 2 Dosing Of BRTX-100; Spine Program Advances Toward 2027 Data RTTNews · May 26, 2026
- What Makes Biorestorative Therapies (BRTX) a New Buy StockZacks · May 15, 2026
The company
BioRestorative Therapies, Inc. ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs relate to the treatment of disc/spine disease (our lead cell therapy candidate, BRTX-100, is currently in a Phase 2 clinical trial for the treatment of chronic lumbar disc disease) and metabolic disorders (our ThermoStem Program). We have also developed a commercial biocosmeceutical platform through which we formulate, manufacture and sell cell-based biologic aesthetic products.
- Sector
- Health Care
- Industry
- Managed Health Care
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- biorestorative.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.